The Woodlands, Texas, September 10, 2019 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that clinical data for Zynquista (sotagliflozin) will be presented at the upcoming European Association for the Study of Diabetes (EASD) 55th annual meeting (September 16-20; Barcelona, Spain). The accepted abstracts, including two oral presentations, reflect Lexicon’s efforts to address the unmet need for new options for the management of type 1 diabetes.

Oral Presentations (all times local)

  • Tuesday, September 17, 10:15 am-11:45 am; Session OP 01: “SGLT2 Inhibitors: Glucose and Beyond”; Joslin Hall
    • “Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, in Overweight/Obese Patients with Type 1 Diabetes: Addressing Unmet Needs as Adjunct Therapy to Insulin” (Abstract #2)
    • “Effect of Sotagliflozin on Body Weight and Composition in Adults with Type 1 Diabetes” (Abstract #3)


  • Wednesday, September 18, 12:00 pm-1:00 pm; Session PS 051: “SGLT2 Inhibitors in Type 1 Diabetes: Benefits and Harms”; Poster Hall
    • “Sotagliflozin Reduces Glucose Variability and Risk for Hyperglycemia in Adults with Type 1 Diabetes” (Abstract #717)
    • “Improved Treatment Satisfaction in Patients with Type 1 Diabetes Treated with Sotagliflozin Plus Insulin vs. Insulin Alone” (Abstract #724)
  • Wednesday, September 18, 12:00 pm-1:00 pm; Session PS 065: “Clinical Aspects of Hypoglycemia”; Poster Hall
    • “Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at Week 52 in Adults with Type 1 Diabetes” (Abstract #849)
  • Wednesday, September 18, 1:15 pm-2:15 pm; Session PS 082: “Promising Therapeutic Options for Diabetic Kidney Disease”; Poster Hall
    • “The Impact of Sotagliflozin on Renal Function, Albuminuria and Blood Pressure in Adults with Type 1 Diabetes” (Abstract #1000)
  • Wednesday, September 18, 1:15 pm-2:15 pm; Session PS 100: Treatment of Cardiovascular Disease"; Poster Hall
    • “Sotagliflozin Reduces Markers of Arterial Stiffness in Type 1 Diabetes: Pooled Analysis from inTandem1 and inTandem2 Clinical Trials” (Abstract #1166)


About Zynquista (sotagliflozin)

Discovered using Lexicon’s unique approach to gene science, Zynquista is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract, and SGLT2 is responsible for glucose reabsorption by the kidney. Zynquista is approved in the European Union (EU) for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes with a body mass index ≥ 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy. Outside of such approval, Zynquista is investigational and has not been approved by any other regulatory authority for type 1 or type 2 diabetes.

About Lexicon Pharmaceuticals

Lexicon is a fully integrated biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. In addition to its first commercial product, XERMELO, Lexicon has a pipeline of promising drug candidates in clinical and preclinical development in diabetes and metabolism, oncology and neuropathic pain. For additional information, please visit

Safe Harbor Statement

This press release contains “forward-looking statements,” including statements relating to Lexicon’s long-term outlook on its business, the commercialization of XERMELO (telotristat ethyl) and Zynquista (sotagliflozin), and the clinical development of, the regulatory filings for, and the potential therapeutic and commercial potential of telotristat ethyl, sotagliflozin, LX2761 and LX9211. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize XERMELO, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of telotristat ethyl, sotagliflozin, LX2761, LX9211 and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2018, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For Investor Inquiries:

Kimberly Lee, D.O.
Head of Investor Relations and Corporate Strategy
Lexicon Pharmaceuticals
(281) 863-3383
This email address is being protected from spambots. You need JavaScript enabled to view it.

For Media Inquiries:

Chas Schultz
Executive Director, Corporate Communications and Patient Advocacy
Lexicon Pharmaceuticals
(281) 863-3421
This email address is being protected from spambots. You need JavaScript enabled to view it.